Hospitals/Medical Services — sector analysis & key numbers
Hospitals/Medical Services is mid-way through a confirmed up-move: 6 of 7 constituents are in price uptrends, and aggregate profit grew 40% in the latest year.
Hospitals/Medical Services groups 7 listed companies worth ₹37,578 Cr combined, and 6 of 7 are in confirmed price uptrends. Aggregate profit moved +31.8% year-on-year in the latest reported quarter. The sector trades at an aggregate P/E of 46.0×, at the 75th percentile of its own history.
Data as of 1 July 2026 · every number traces to its Screener source column · not investment advice.
- Companies
- 7
- Total market cap
- ₹37,578 Cr
- Relative strength
- 24
- RRG quadrant
- broadening
- Weeks in streak
- 12
- In Stage-2 uptrend
- 6 of 7
- Above 200-DMA
- 7 of 7
- Beating NIFTY 500
- 2 of 7
- Latest-quarter revenue
- ₹1,469 Cr
- Latest-quarter profit
- ₹199 Cr
- Aggregate P/E
- 46.0×
- Valuation percentile
- 75th of its own history
- Sector wind
- strong tailwind
- Data as of
- 1 July 2026
The research read on Hospitals/Medical Services: mid-way through a confirmed up-move.lifecycle_bucket
All three streams agree on macro direction — a secular, defensive, structurally-growing demand cycle — and the curve genuinely confirms it: a real EPS-led compounder (revenue ~9x to ₹5,178 Cr, PAT -₹22→₹626 Cr, OPM stable 25-28%, PE cooled 116.65→46.03 while price held near its high). Aggregate ΣPAT rose +40.4% YoY and the dominant leg was revenue (+26.1%, the durable volume/demand kind), not a margin trick. The deterministic ground rates it fairly priced with margins near mid-cycle (71st percentile) and trailing/normalized PE agreeing — no cyclical distortion to harvest. Qual is the high-water mark (a strong tailwind / strong / worth studying deeper, expansion) and social is bullish-rising. The disagreements that cap conviction: (1) qual's worth studying deeper is conditional on proven large-caps (Apollo/Max/KIMS) yet the curve constituents are the unproven 2025-26 IPO micro-cap cohort; (2) social is a Pharma super-group halo, not hospital-operator-specific; (3) capital-flows reads entering but decomposes to institutions absent (FII/DII -0.015 over 2q, +0.14 over 4q) with a supply flood capex surge (capex +39.2% YoY, CWIP +79.3%) tagged capacity risk — the inflow is build-out capital arriving late, not institutional crowding, and a sector-wide bed glut competes for returns over the ramp window; (4) SILVER confidence on 7 names with thin early pricing.synthesis
What would change this view: If the next two prints show aggregate OPM rolling down out of its tight 25-28% band as the supply flood of new beds (CWIP +79.3%) ramps faster than occupancy fills, then the fairly-priced young compounder becomes a margin-diluting capacity glut and conviction should fall — watch the OPM curve against the capex/CWIP build.would_change_my_mind
Structural multi-year bed-led growth cycle (18-20% CAGR to 2029) with ARPOB compounding, ICRA Positive outlook and tariff-immune domestic demand — a defensive compounder with near-term gestation/margin drag.one_line_thesis
- ✓Aggregate revenue scaled ~9.4x from ₹553 Cr (2020) to ₹5,178 Cr (2026) on a widening reporter base (2→7). · hospitals-medical-services.json (curve.annual_fundamentals)
- ✓PAT swung from a -₹22 Cr Covid loss (2020) to ₹626 Cr (2026), with a mild FY24 air-pocket to ₹307 Cr. · hospitals-medical-services.json (curve.annual_fundamentals)
- ✓OPM stable in a 22.8-28.3% band, latest 26.79%. · hospitals-medical-services.json (curve.annual_fundamentals)
- ✓Sector PE rose from a 19.01 trough (2024-06) to a 116.65 peak (2025-03) then mean-reverted to 46.03 latest; PB cooled from an 8.06 peak (2025-09) to 4.95. · hospitals-medical-services.json (curve.valuation_series)
- ⚠Price index held near its high (124.3 peak 2025-12, 122.0 latest) — multiple compression absorbed by rising earnings. · hospitals-medical-services.json (curve.valuation_series)
- ⚠Deterministic verdict fairly priced: OPM 26.8% at 71st percentile (amplitude 1.24x, flat) vs mid-cycle 26.4%; trailing PE 55th → normalized PE 64th percentile (Δ-9 pts) — surface and normalized agree. · hospitals-medical-services.json (sector_cycle_deterministic.verdict)
- ✓Capital-flows read entering but institutions absent (FII/DII -0.015 over 2q, +0.14 over 4q); the inflow is a capex supply flood (capex +39.17% YoY, CWIP +79.33%) tagged capacity risk; promoters +0.26. · hospitals-medical-services.json (capital_flows)
- ✓SILVER confidence on 7 names with a price series only 1-7 priced names early on (n_priced ramps to 7). · hospitals-medical-services.json (curve)
Research view from 2026-06-27
Across the 3 largest constituents with research timelines, 2 carried trackable guidance: 1 beat, 0 met, 5 misses against what management said.guidance_pairs
Research view from 2026-06-27
6 of 7 constituents are in Stage-2 price uptrends, 7 trade above their 200-day averages, and 2 are beating the NIFTY 500 on relative strength.stageabove_dma200rs_mansfield
Over the trailing ~20 weeks, the share of constituents above the 200-day line moved from 83% to 100% — participation is widening.breadth_series
Sector relative strength stands at 24, in the broadening quadrant of the rotation map, with relative strength falling over a 12-week streak.current_rsquadrant
Recent stage changes: AGARWALEYE (stage 4→1).stage
Data: Breadth trend
| Period | % above 200-DMA (%) | % beating NIFTY (%) |
|---|---|---|
| Feb 26 | 83.3 | 50.0 |
| Feb 26 | 83.3 | 50.0 |
| Feb 26 | 83.3 | 100.0 |
| Mar 26 | 83.3 | 100.0 |
| Mar 26 | 83.3 | 50.0 |
| Mar 26 | 83.3 | 100.0 |
| Mar 26 | 50.0 | 100.0 |
| Mar 26 | 80.0 | 100.0 |
| Apr 26 | 85.7 | 50.0 |
| Apr 26 | 85.7 | 50.0 |
| Apr 26 | 85.7 | 50.0 |
| Apr 26 | 85.7 | 50.0 |
| May 26 | 100.0 | 100.0 |
| May 26 | 85.7 | 100.0 |
| May 26 | 100.0 | 100.0 |
| May 26 | 100.0 | 100.0 |
| Jun 26 | 100.0 | 100.0 |
| Jun 26 | 85.7 | 50.0 |
| Jun 26 | 100.0 | 100.0 |
| Jun 26 | 100.0 | 100.0 |
Data as of 2026-07-01
Top performers by 1-year price return: Unihealth Hospitals Ltd (+265.4%), Dr Agarwals Health Care Ltd (+12.6%), Park Medi World Ltd (return unavailable), Nephrocare Health Services Ltd (return unavailable), Gujarat Kidney & Super Speciality Ltd (return unavailable).price
Data: Indexed price (base 100, ~52 weeks) — default top-5
| Period | UNIHEALTH (index) | AGARWALEYE (index) | PARKHOSPS (index) | NEPHROPLUS (index) | GKSL (index) | Sector avg (index) |
|---|---|---|---|---|---|---|
| Jul 25 | 100 | 100 | – | – | – | 100 |
| Jul 25 | 100 | 103 | – | – | – | 101 |
| Jul 25 | 99.5 | 107 | – | – | – | 103 |
| Aug 25 | 99.4 | 106 | – | – | – | 103 |
| Aug 25 | 95.0 | 104 | – | – | – | 99.5 |
| Aug 25 | 95.8 | 110 | – | – | – | 103 |
| Aug 25 | 96.9 | 107 | – | – | – | 102 |
| Aug 25 | 95.3 | 101 | – | – | – | 98.3 |
| Sep 25 | 100 | 99.6 | – | – | – | 99.8 |
| Sep 25 | 98.8 | 102 | – | – | – | 100 |
| Sep 25 | 102 | 107 | – | – | – | 104 |
| Sep 25 | 89.9 | 114 | – | – | – | 102 |
| Oct 25 | 97.8 | 117 | – | – | – | 107 |
| Oct 25 | 95.9 | 125 | – | – | – | 111 |
| Oct 25 | 94.9 | 128 | – | – | – | 111 |
| Oct 25 | 95.3 | 122 | – | – | – | 109 |
| Oct 25 | 99.4 | 119 | – | – | – | 109 |
| Nov 25 | 93.2 | 118 | – | – | – | 106 |
| Nov 25 | 97.3 | 123 | – | – | – | 110 |
| Nov 25 | 190 | 116 | – | – | – | 153 |
| Nov 25 | 199 | 125 | – | – | – | 162 |
| Dec 25 | 172 | 118 | – | – | – | 145 |
| Dec 25 | 184 | 118 | – | – | – | 151 |
| Dec 25 | 181 | 117 | 100 | 100 | – | 125 |
| Dec 25 | 161 | 118 | 93.9 | 106 | – | 120 |
| Jan 26 | 184 | 118 | 96.7 | 106 | 100 | 121 |
| Jan 26 | 174 | 118 | 96.0 | 111 | 99.5 | 120 |
| Jan 26 | 175 | 114 | 97.8 | 113 | 100 | 120 |
| Jan 26 | 161 | 107 | 101 | 113 | 96.7 | 116 |
| Feb 26 | 176 | 104 | 97.3 | 116 | 102 | 116 |
| Feb 26 | 176 | 105 | 98.9 | 118 | 109 | 119 |
| Feb 26 | 174 | 107 | 113 | 128 | 108 | 127 |
| Feb 26 | 186 | 104 | 119 | 124 | 108 | 128 |
| Feb 26 | 194 | 106 | 125 | 132 | 111 | 131 |
| Mar 26 | 197 | 104 | 131 | 126 | 105 | 130 |
| Mar 26 | 203 | 100 | 124 | 120 | 106 | 128 |
| Mar 26 | 234 | 99.3 | 129 | 119 | 103 | 133 |
| Mar 26 | 226 | 95.9 | 129 | 117 | 99.5 | 129 |
| Apr 26 | 233 | – | 127 | 118 | 101 | 138 |
| Apr 26 | 270 | 102 | 136 | 125 | 105 | 137 |
| Apr 26 | 287 | 104 | 140 | 130 | 109 | 145 |
| Apr 26 | 302 | 103 | 150 | 119 | 110 | 150 |
| Apr 26 | 284 | 104 | 149 | 118 | 122 | 149 |
| May 26 | 261 | 106 | 161 | 121 | 136 | 152 |
| May 26 | 274 | 105 | 158 | 143 | 134 | 153 |
| May 26 | 273 | 112 | 167 | 135 | 140 | 156 |
| May 26 | 255 | 113 | 186 | 133 | 134 | 157 |
| Jun 26 | 271 | 108 | 182 | 151 | 128 | 156 |
| Jun 26 | 280 | 103 | 177 | 167 | 127 | 158 |
| Jun 26 | 335 | 109 | 179 | 163 | 125 | 167 |
| Jun 26 | 340 | 113 | 184 | 147 | 126 | 169 |
| Jul 26 | 362 | 110 | 191 | 151 | 128 | 174 |
Data: Quarterly revenue (8q) — default top-5
| Period | UNIHEALTH (₹ Cr) | AGARWALEYE (₹ Cr) | PARKHOSPS (₹ Cr) | NEPHROPLUS (₹ Cr) | GKSL (₹ Cr) | Sector avg (₹ Cr) |
|---|---|---|---|---|---|---|
| Jun 24 | – | 403 | – | – | – | 403 |
| Sep 24 | 43.0 | 417 | – | – | 9.0 | 125 |
| Dec 24 | – | 431 | 348 | 197 | 12.0 | 200 |
| Mar 25 | 56.0 | 460 | 354 | 219 | 10.0 | 167 |
| Jun 25 | – | 487 | – | – | 15.0 | 251 |
| Sep 25 | 67.0 | 499 | 410 | 246 | 13.0 | 188 |
| Dec 25 | – | 530 | 410 | 260 | 23.0 | 250 |
| Mar 26 | 65.0 | 564 | 460 | 266 | 31.0 | 210 |
Data: Quarterly net profit (8q) — default top-5
| Period | UNIHEALTH (₹ Cr) | AGARWALEYE (₹ Cr) | PARKHOSPS (₹ Cr) | NEPHROPLUS (₹ Cr) | GKSL (₹ Cr) | Sector avg (₹ Cr) |
|---|---|---|---|---|---|---|
| Jun 24 | – | 18.0 | – | – | – | 18.0 |
| Sep 24 | 9.0 | 21.0 | – | – | 3.0 | 10.3 |
| Dec 24 | – | 28.0 | 46.0 | 20.0 | 3.0 | 20.0 |
| Mar 25 | 18.0 | 43.0 | 52.0 | 25.0 | 1.0 | 21.4 |
| Jun 25 | – | 38.0 | – | – | 5.0 | 21.5 |
| Sep 25 | 29.0 | 36.0 | 79.0 | -9.0 | 3.0 | 22.1 |
| Dec 25 | – | 44.0 | 53.0 | 32.0 | 4.0 | 27.4 |
| Mar 26 | 17.0 | 50.0 | 77.0 | 30.0 | 5.0 | 28.4 |
Data: Operating margin % (8q) — default top-5
| Period | UNIHEALTH (%) | AGARWALEYE (%) | PARKHOSPS (%) | NEPHROPLUS (%) | GKSL (%) | Sector avg (%) |
|---|---|---|---|---|---|---|
| Jun 24 | – | 26.0 | – | – | – | 26.0 |
| Sep 24 | 35.0 | 26.0 | – | – | 51.6 | 38.1 |
| Dec 24 | – | 27.0 | 24.0 | 22.0 | 39.0 | 30.3 |
| Mar 25 | 38.0 | 28.0 | 25.0 | 23.0 | 26.7 | 27.7 |
| Jun 25 | – | 26.0 | – | – | 56.5 | 41.3 |
| Sep 25 | 48.0 | 27.0 | 27.0 | 26.0 | 39.6 | 34.0 |
| Dec 25 | – | 27.0 | 24.0 | 23.0 | 29.7 | 26.1 |
| Mar 26 | 34.0 | 29.0 | 28.0 | 19.0 | 20.6 | 29.1 |
Data: Latest reported ROCE / ROE (single latest reading, not a trend) — default top-5
| Period | UNIHEALTH (%) | AGARWALEYE (%) | PARKHOSPS (%) | NEPHROPLUS (%) | GKSL (%) | Sector avg (%) |
|---|---|---|---|---|---|---|
| ROCE % | 27.4 | 11.1 | 19.3 | 15.5 | 14.5 | 21.8 |
| ROE % | 21.4 | 6.8 | 16.7 | 9.1 | 11.1 | 17.0 |
Data: 10-year valuation percentile (latest) — default top-5
| Period | UNIHEALTH (percentile) | AGARWALEYE (percentile) | PARKHOSPS (percentile) | GKSL (percentile) | Sector avg (percentile) |
|---|---|---|---|---|---|
| 10y percentile | 50.0 | 0.0 | 75.0 | 75.0 | 50.0 |
Interactive charts default to the five strongest performers by 1-year price return; use the rail to add or remove any constituent, globally or per chart. Non-interactive readers see the same numbers in each chart’s data table.
Data as of 2026-07-01
In the latest reported quarter (2026-03), constituents together booked ₹1,469 Cr of revenue (+25.9% year-on-year) and ₹199 Cr of profit (+31.8%).revenuepat
On the annual arc, aggregate profit grew 40% to ₹626 Cr in 2026.pat
Data: Aggregate quarterly revenue
| Period | Revenue (₹ Cr) | Reporters |
|---|---|---|
| Jun 23 | – | 0 |
| Sep 23 | 22 | 1 |
| Dec 23 | 333 | 1 |
| Mar 24 | 376 | 2 |
| Jun 24 | 403 | 1 |
| Sep 24 | 501 | 4 |
| Dec 24 | 1,002 | 5 |
| Mar 25 | 1,167 | 7 |
| Jun 25 | 502 | 2 |
| Sep 25 | 1,315 | 7 |
| Dec 25 | 1,248 | 5 |
| Mar 26 | 1,469 | 7 |
Data: Aggregate quarterly profit
| Period | Profit after tax (₹ Cr) |
|---|---|
| Jun 23 | – |
| Sep 23 | 4 |
| Dec 23 | 23 |
| Mar 24 | 47 |
| Jun 24 | 18 |
| Sep 24 | 41 |
| Dec 24 | 100 |
| Mar 25 | 151 |
| Jun 25 | 43 |
| Sep 25 | 155 |
| Dec 25 | 136 |
| Mar 26 | 199 |
Data: Aggregate operating margin
| Period | OPM (%) |
|---|---|
| Jun 23 | – |
| Sep 23 | 31.8 |
| Dec 23 | 26.7 |
| Mar 24 | 31.4 |
| Jun 24 | 25.8 |
| Sep 24 | 27.9 |
| Dec 24 | 25.2 |
| Mar 25 | 26.6 |
| Jun 25 | 27.2 |
| Sep 25 | 28.7 |
| Dec 25 | 25.4 |
| Mar 26 | 27.1 |
Data: Aggregate profit by year
| Period | Profit after tax (₹ Cr) |
|---|---|
| 2020 | -22 |
| 2021 | 134 |
| 2022 | 234 |
| 2023 | 349 |
| 2024 | 307 |
| 2025 | 446 |
| 2026 | 626 |
Data: Operating margin by year
| Period | OPM (%) |
|---|---|
| 2020 | 22.8 |
| 2021 | 28.3 |
| 2022 | 26.4 |
| 2023 | 26.3 |
| 2024 | 25.1 |
| 2025 | 26.5 |
| 2026 | 26.8 |
Data as of 2026-06-27
Sector profit moved from ₹446 Cr to ₹626 Cr (+40.4% year-on-year) — the decomposition attributes the larger share to the revenue side (demand and volumes).pat
Sector revenue moved from ₹4,105 Cr to ₹5,178 Cr (+26.1% year-on-year).revenue
Capital cycle: capital is entering this industry, with constituent capex running +39.2% year-on-year.readcapex_yoy_pct
Sector ΣPAT +40.4% YoY — dominant leg: revenue (volume/demand-led — the durable kind).
patSector Σrevenue +26.1% YoY — confirm it is demand/volume-led across constituents, not price/base.
revenueCapital is ENTERING (read=ENTERING; capex +39.17%, FII+DII +0.14pp) — crowding in + a capex surge LATE in the cycle is a HEADWIND (supply coming, competition for returns). Check whether the inflow is EARLY (depressed valuation, fresh turn) or LATE (chasing a run).
capex_yoy_pctfii_dii_delta_4qcwip_growth_pctResearch view from 2026-06-27
Ownership: institutional (FII+DII) holdings moved +0.14 percentage points over four quarters; promoter stakes moved +0.26 points over two.fii_dii_delta_4qpromoter_delta_2q
Constituents spent ₹1,407 Cr on capex in the trailing twelve months (+39.2% year-on-year), with gross block growing +26.5%.capex_ttm_sum_crcapex_yoy_pct
On the deterministic capital-flow read, capital is entering this industry.read
Research view from 2026-06-27
The sector trades at an aggregate P/E of 46.03× against a range of 19.01–116.65× over its 40-quarter history.pe
The median constituent sits at the 75th percentile of its own 10-year valuation range.percentile
Aggregate operating margin (26.8%) sits at the 86th percentile of its own annual history — a cheap-looking multiple on near-peak margins is only cheap if the margins hold.opm
Valuation history is short (11 quarters of aggregate P/E) — percentile comparisons carry less weight.opm
Data: Aggregate P/E and price index
| Period | P/E (×) | Price index |
|---|---|---|
| Jun 16 | – | – |
| Sep 16 | – | – |
| Dec 16 | – | – |
| Mar 17 | – | – |
| Jun 17 | – | – |
| Sep 17 | – | – |
| Dec 17 | – | – |
| Mar 18 | – | – |
| Jun 18 | – | – |
| Sep 18 | – | – |
| Dec 18 | – | – |
| Mar 19 | – | – |
| Jun 19 | – | – |
| Sep 19 | – | – |
| Dec 19 | – | – |
| Mar 20 | – | – |
| Jun 20 | – | – |
| Sep 20 | – | – |
| Dec 20 | – | – |
| Mar 21 | – | – |
| Jun 21 | – | – |
| Sep 21 | – | – |
| Dec 21 | – | – |
| Mar 22 | – | – |
| Jun 22 | – | – |
| Sep 22 | – | – |
| Dec 22 | – | – |
| Mar 23 | – | – |
| Jun 23 | – | – |
| Sep 23 | 25.5 | 100 |
| Dec 23 | 25.5 | 100 |
| Mar 24 | 21.5 | 105 |
| Jun 24 | 19.0 | 93 |
| Sep 24 | 25.4 | 125 |
| Dec 24 | 22.7 | 112 |
| Mar 25 | 116.7 | 109 |
| Jun 25 | 90.3 | 98 |
| Sep 25 | 100.4 | 120 |
| Dec 25 | 60.6 | 124 |
| Mar 26 | 46.0 | 122 |
Aggregate operating margin (26.8%) sits at the 86th percentile of its own annual history — a cheap-looking multiple on near-peak margins is only cheap if the margins hold.
Valuation history is short (11 quarters of aggregate P/E) — percentile comparisons carry less weight.
Data as of 2026-06-27
7 companies make up this sector, led by Dr Agarwals Health Care Ltd at ₹15,363 Cr of market value.constituents
| Company | Price | 1y | Stage | RS | 10y val % |
|---|---|---|---|---|---|
| Dr Agarwals Health Care Ltd | ₹469 | +12.6% | 1 | 0.2 | 0 |
| Park Medi World Ltd | ₹295 | – | 2 | – | 75 |
| Nephrocare Health Services Ltd | ₹679 | – | 2 | – | – |
| Gujarat Kidney & Super Speciality Ltd | ₹131 | – | 2 | – | 75 |
| Unihealth Hospitals Ltd | ₹612 | +265.4% | 2 | 98.7 | 50 |
| Gaudium IVF and Women Health Ltd | ₹115 | – | 2 | – | – |
| KRM Ayurveda Ltd | ₹257 | – | 2 | – | – |
Data as of 2026-07-01
Headwind chain: A secular, defensive healthcare-services demand cycle under a +10% healthcare budget, cited as a tailwind/strong/worth studying deeper across Hospitals (Q1 bed commissioning, FY27 EBITDA 21-25%), Diagnostics (Q1/Q2 volume-tsunami… Also touches: Hospitals, Diagnostics.triggermechanism
Tailwind chain: K-shaped recovery where high-income consumers drive discretionary spending. Also touches: Hotels, Watches, Textiles - Readymade Apparel.triggermechanism
A secular, defensive healthcare-services demand cycle under a +10% healthcare budget, cited as a tailwind/strong/worth studying deeper across Hospitals (Q1 bed commissioning, FY27 EBITDA 21-25%), Diagnostics (Q1/Q2 volume-tsunami + operating-leverage, VIJAYA +221bps) and Hospitals/Medical Services (Q1 early-cycle) — all on capacity discipline (Hospitals capex -19.6% YoY, an ideal trough setup).
Non-discretionary medical demand + PPP/network capacity commissioning drives earnings-led operating leverage that is structurally uncorrelated to the capex/commodity/freight cycles taxing the industrial complex — a defensive hedge that earns through the same fortnight's macro shocks (Hormuz, private-capex slump, metal costs).
K-shaped recovery where high-income consumers drive discretionary spending.
Strong demand for premium healthcare, hospitality, and accessories drives margin expansion.
Research view from 2026-06-27
A breakdown is NOT underway: 100% of constituents still trade above their 200-day averages.breadth_series
- A breakdown is NOT underway: 100% of constituents still trade above their 200-day averages.
Data as of 2026-07-01
Straight answers from the data
What is the Hospitals/Medical Services sector?
The Hospitals/Medical Services sector groups 7 listed companies with a combined market value of ₹37,578 Cr, led by Dr Agarwals Health Care Ltd, Park Medi World Ltd, Nephrocare Health Services Ltd. 6 of 7 constituents are currently in confirmed price uptrends.
Which stocks are in the Hospitals/Medical Services sector?
The largest Hospitals/Medical Services companies by market value are Dr Agarwals Health Care Ltd (₹15,363 Cr), Park Medi World Ltd (₹12,332 Cr), Nephrocare Health Services Ltd (₹6,602 Cr), Gujarat Kidney & Super Speciality Ltd (₹1,019 Cr), Unihealth Hospitals Ltd (₹914 Cr), Gaudium IVF and Women Health Ltd (₹791 Cr), KRM Ayurveda Ltd (₹557 Cr).
What are the best-performing Hospitals/Medical Services stocks?
By 1-year price return as of 1 July 2026, the strongest Hospitals/Medical Services stocks are Unihealth Hospitals Ltd (+265%), Dr Agarwals Health Care Ltd (+13%), Park Medi World Ltd (+97%, 6-month, listed within the past year), Nephrocare Health Services Ltd (+43%, 6-month, listed within the past year), Gujarat Kidney & Super Speciality Ltd (+28%, 6-month, listed within the past year). These are descriptive price moves measured from weekly Screener closes, not recommendations.
Is the Hospitals/Medical Services sector in an uptrend?
6 of 7 Hospitals/Medical Services constituents are in Stage-2 price uptrends, 7 trade above their 200-day average, and 2 are beating the NIFTY 500 on relative strength. Sector relative strength reads 24, in the broadening quadrant of the rotation map, falling over a 12-week streak.
How many Hospitals/Medical Services stocks trade above their 200-day average?
7 of 7 Hospitals/Medical Services constituents currently trade above their 200-day moving average. Over the trailing ~20 weeks, that share moved from 83% to 100% — participation is widening.
Is the Hospitals/Medical Services sector expensive versus its own history?
The Hospitals/Medical Services sector trades at an aggregate P/E of 46.0× against a 19.0–117× band over its own history. The median constituent sits at the 75th percentile of its own 10-year P/E range, above the middle of its own historical range. Aggregate operating margin (26.8%) sits at the 86th percentile of its own annual history — a cheap-looking multiple on near-peak margins is only cheap if the margins hold.
Is money entering or leaving the Hospitals/Medical Services sector?
On Sector Alpha's deterministic capital-flow read, money is entering the Hospitals/Medical Services sector. Institutional (FII+DII) holdings moved +0.14 percentage points across constituents over the last four quarters, and constituents grew capex +39.2% year-on-year.
How fast is the Hospitals/Medical Services sector growing?
In the latest reported quarter (March 2026), Hospitals/Medical Services constituents together booked ₹1,469 Cr of revenue, +25.9% year-on-year, with aggregate profit +31.8% year-on-year. Figures aggregate Screener-scraped quarterly filings across the sector.
How are Hospitals/Medical Services operating margins trending?
Aggregate Hospitals/Medical Services operating margin was 27.1% in the latest reported quarter (March 2026), versus 26.6% a year earlier — margins are improving.
Which sectors is the Hospitals/Medical Services sector connected to?
The Hospitals/Medical Services sector sits in 2 cross-sector chains: as a potential casualty it connects to Hospitals, Diagnostics — A secular, defensive healthcare-services demand cycle under a +10% healthcare budget, cited as a tailwind/strong/worth studying deeper across Hospitals (Q1 bed…; as a beneficiary it connects to Hotels, Watches, Textiles - Readymade Apparel — K-shaped recovery where high-income consumers drive discretionary spending..
What is the bull case for the Hospitals/Medical Services sector?
Structural multi-year bed-led growth cycle (18-20% CAGR to 2029) with ARPOB compounding, ICRA Positive outlook and tariff-immune domestic demand — a defensive compounder with near-term gestation/margin drag. Aggregate revenue scaled ~9.4x from ₹553 Cr (2020) to ₹5,178 Cr (2026) on a widening reporter base (2→7).
What could change the view on the Hospitals/Medical Services sector?
If the next two prints show aggregate OPM rolling down out of its tight 25-28% band as the supply flood of new beds (CWIP +79.3%) ramps faster than occupancy fills, then the fairly-priced young compounder becomes a margin-diluting capacity glut and conviction should fall — watch the OPM curve against the capex/CWIP build. Also worth noting: a breakdown is NOT underway: 100% of constituents still trade above their 200-day averages.
What is the research view on the Hospitals/Medical Services sector?
Sector Alpha does not publish trading recommendations or price calls — this is a research read, not advice. What the data says: broken out mid · mixed. All three streams agree on macro direction — a secular, defensive, structurally-growing demand cycle — and the curve genuinely confirms it: a real EPS-led compounder (revenue ~9x to ₹5,178 Cr, PAT -₹22→₹626 Cr, OPM stable 25-28%, PE cooled 116.65→46.03 while price held near its high). Every number on this page traces to its source column; it is machine-written research, not investment advice.
Should I invest in the Hospitals/Medical Services sector?
Sector Alpha does not publish sector allocations or trading calls — for Hospitals/Medical Services or any sector. What this page provides is a data-first read: how many constituents are in confirmed uptrends, how the sector's valuation compares with its own history, where earnings sit in their cycle, and whether capital is entering or leaving. Use it to study the sector on the evidence, then do your own diligence.
What is the Hospitals/Medical Services sector's relative-strength position?
Hospitals/Medical Services relative strength reads 24 on Sector Alpha's rotation map, placing it in the broadening quadrant. Relative strength is falling and has held for 12 weeks. A positive, rising relative-strength trend means the sector has been outperforming the broad market week after week.